Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration and Inflammation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for JNK/MAPK8/JNK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAPK8/JNK1 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for kinase assays and SPR. |
View MAPK8 Products |
| Gene Delivery | MAPK8/JNK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and reporter assays. |
View MAPK8 Products |
| Benchmark Ab | Anti-MAPK8/JNK1 Reference Antibody Recombinant positive control for Western Blot, ELISA, and IP validation. |
View MAPK8 Products |
| Validator | MAPK8/JNK1 siRNA Set For knockdown verification in functional pathway validation. |
View MAPK8 Products |
| Related Target A | MAPK9/JNK2 Subfamily homolog. Crucial for selectivity profiling to prevent off-target toxicity. |
View MAPK9 Products |
| Related Target B | MAPK10/JNK3 Brain-specific isoform. Vital counter-screening target for neurodegenerative indications. |
View MAPK10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (JNK1 vs JNK2/3) | High-purity recombinant MAPK8, MAPK9, and MAPK10 panels strictly verified by mass spectrometry. |
| Assay Reproducibility | Batch-to-batch consistency with verified theoretical MW and high purity (>95% by SDS-PAGE). |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression plasmids. |
| False Positives in Screening | Sequence-validated siRNA pools included for target-specific knockdown verification. |
Live JNK/MAPK8/JNK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JNK/MAPK8/JNK1 therapeutics is intensifying, with major players shifting focus from traditional ATP-competitive small molecules to highly selective covalent inhibitors and allosteric modulators. As first-generation pan-JNK inhibitors faced clinical limitations due to off-target toxicities (particularly cardiovascular and hepatic side effects), the next wave of R&D is targeting isoform-specific inhibition and targeted protein degradation (PROTACs) to achieve a wider therapeutic window.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Isoform-selective) | Bristol Myers Squibb, Benten Biotech | Fibrotic Diseases, NASH, Neurodegeneration | Selectivity Assay (Need JNK1 vs JNK2/3 recombinant proteins) |
| PROTAC (Degrader) | Academic & Biotech Consortia | Oncology, Inflammatory Disorders | Degradation Kinetics (Need Lentivirus for stable reporter cell lines) |
| Peptide Inhibitors | Xigen, D-Pharm | Ophthalmic Diseases, Stroke | Binding Affinity Verification (Need high-purity active enzyme) |